Epigenetic Biomarkers in Colorectal Cancer

Developments in the diagnosis and treatment of colorectal cancer (CRC) have been made in the last decade, but the overall survival rate of patients with CRC has not improved dramatically. Genetic and epigenetic events contribute to CRC pathogenesis. Tumor heterogeneity results in a range of prognoses and responses to CRC management and therapy. Epigenetic biomarkers have potential in CRC diagnosis and in measuring response to therapy. Combining information from genetic and epigenetic alterations provides an opportunity to predict response to therapy. Epigenetic biomarkers can be used in disease stratification, which also helps in designing therapeutic approaches for CRC. Challenges in the understanding of CRC development and gaps in knowledge are discussed.

[1]  I. Zlobec,et al.  Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer , 2013, Front. Oncol..

[2]  F. Sinicrope,et al.  Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  P. Jin,et al.  DNA methylation and hydroxymethylation in stem cells , 2015, Cell biochemistry and function.

[4]  Rong-gang Ma,et al.  Epigenetic regulation by polycomb group complexes: focus on roles of CBX proteins , 2014, Journal of Zhejiang University SCIENCE B.

[5]  Zhong-fa Xu,et al.  Expression and mechanism of microRNA-181A on incidence and survival in late liver metastases of colorectal cancer. , 2016, Oncology Report.

[6]  J. Carethers.  Biomarker-directed Targeted Therapy in Colorectal Cancer. , 2015, Journal of digestive cancer reports.

[7]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[8]  A. Kalmár,et al.  DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer , 2015, BMC Cancer.

[9]  D. Alberts,et al.  Vitamin D, Calcium, and Colorectal Neoplasia: New Insights on Mechanisms of Action , 2009, Cancer Prevention Research.

[10]  P. Mummaneni,et al.  Epigenetics and Oncology , 2014, Pharmacotherapy.

[11]  Y. Toiyama,et al.  miRNA-503 Promotes Tumor Progression and Is Associated with Early Recurrence and Poor Prognosis in Human Colorectal Cancer , 2016, Oncology.

[12]  John K Gohagan,et al.  The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. , 2004, Urologic oncology.

[13]  M. Khoury,et al.  Epigenetic Research in Cancer Epidemiology: Trends, Opportunities, and Challenges , 2013, Cancer Epidemiology, Biomarkers and Prevention.

[14]  M. Bertagnolli,et al.  CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. , 2014, Gastroenterology.

[15]  M. Verma.  Genome-wide association studies and epigenome-wide association studies go together in cancer control. , 2016, Future oncology.

[16]  D. Lieberman,et al.  Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. , 2017, Gastrointestinal endoscopy.

[17]  Ju-Seog Lee,et al.  CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer , 2015, Oncotarget.

[18]  W. El-Deiry,et al.  Contradictory KRAS mutation test results in a patient with metastatic colon cancer , 2013, Cancer biology & therapy.

[19]  Y. Ba,et al.  MGMT in colorectal cancer: a promising component of personalized treatment , 2016, Tumor Biology.

[20]  F. Coppedè,et al.  Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens , 2014, Epigenetics.

[21]  R. Paro,et al.  Trithorax and Polycomb group-dependent regulation: a tale of opposing activities , 2015, Development.

[22]  Hui Chen,et al.  Hypermethylation-Associated Silencing of miR-125a and miR-125b: A Potential Marker in Colorectal Cancer , 2015, Disease markers.

[23]  M. Toyota,et al.  Fusobacterium in colonic flora and molecular features of colorectal carcinoma. , 2014, Cancer research.

[24]  T. Tuohy,et al.  Hereditary and familial colon cancer. , 2010, Gastroenterology.

[25]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[26]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[27]  C. Boland,et al.  A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer , 2012, PloS one.

[28]  Shinji Tanaka,et al.  Laterally spreading tumors in the colon and rectum , 2012, European journal of gastroenterology & hepatology.

[29]  Mehmet Gürbüzel,et al.  Relationship among mismatch repair deficiency, CDX2 loss, p53 and E-cadherin in colon carcinoma and suitability of using a double panel of mismatch repair proteins by immunohistochemistry. , 2015, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[30]  B. Tang,et al.  Long non-coding RNAs in colorectal cancer , 2015, Oncotarget.

[31]  I. Pakzad,et al.  Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer , 2016, Tumor Biology.

[32]  Alexander Meissner,et al.  Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease , 2013, Modern Pathology.

[33]  R. Majdzadeh,et al.  The effectiveness of FOBT vs. FIT: A meta-analysis on colorectal cancer screening test , 2016, Medical journal of the Islamic Republic of Iran.

[34]  H. Putter,et al.  Age-dependent clinical prognostic value of histone modifications in colorectal cancer. , 2015, Translational research : the journal of laboratory and clinical medicine.

[35]  R. Wolff,et al.  Somatic alterations, metabolizing genes and smoking in rectal cancer , 2009, International journal of cancer.

[36]  Mukesh Verma,et al.  Opportunities and Challenges for Selected Emerging Technologies in Cancer Epidemiology: Mitochondrial, Epigenomic, Metabolomic, and Telomerase Profiling , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[37]  Yazeed A Al-Sheikh,et al.  Expression profiling of selected microRNA signatures in plasma and tissues of Saudi colorectal cancer patients by qPCR , 2015, Oncology letters.

[38]  A. Jemal,et al.  Worldwide Variations in Colorectal Cancer , 2009, CA: a cancer journal for clinicians.

[39]  J. Parkhill,et al.  Modulation of the human gut microbiota by dietary fibres occurs at the species level , 2016, BMC Biology.

[40]  Xia Li,et al.  TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer , 2014, Journal of Cancer Research and Clinical Oncology.

[41]  A. Strongin,et al.  Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer , 2015, Clinical Epigenetics.

[42]  S. Juo,et al.  High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2 , 2016, Oncotarget.

[43]  J. Ott,et al.  KRAS Mutation and Microsatellite Instability: Two Genetic Markers of Early Tumor Development That Influence the Prognosis of Colorectal Cancer , 2010, Annals of Surgical Oncology.

[44]  Xiao-Feng Sun,et al.  DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients , 2012, International journal of oncology.

[45]  C. Hamashima,et al.  Tailored message interventions versus typical messages for increasing participation in colorectal cancer screening among a non-adherent population: A randomized controlled trial , 2016, BMC Public Health.

[46]  B. P. Chatterji,et al.  HDAC Inhibitors as Novel Anti-Cancer Therapeutics. , 2015, Recent patents on anti-cancer drug discovery.

[47]  R. Talamini,et al.  Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC). , 2012, Archives of gerontology and geriatrics.

[48]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2007, Featuring Tumors of the Brain and Other Nervous System , 2011, Journal of the National Cancer Institute.

[49]  Stacey A. Kenfield,et al.  Mediterranean diet and prostate cancer risk and mortality in the Health Professionals Follow-up Study. , 2014, European urology.

[50]  B. Broom,et al.  Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin , 2016, Oncotarget.

[51]  C D Langefeld,et al.  Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. , 1993, The American journal of gastroenterology.

[52]  E. Giovannucci,et al.  Original Contribution A Prospective Study of Duration of Smoking Cessation and Colorectal Cancer Risk by Epigenetics-related Tumor Classification , 2013 .

[53]  N. Habermann,et al.  Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. , 2014, Carcinogenesis.

[54]  Y. Doki,et al.  Down-Regulation of microRNA-132 is Associated with Poor Prognosis of Colorectal Cancer , 2016, Annals of Surgical Oncology.

[55]  S. Advani.  CpG Island Methylator Phenotype in Colorectal Cancer , 2017 .

[56]  Y. Jung,et al.  Field Cancerization in Sporadic Colon Cancer , 2016, Gut and liver.

[57]  I. Zlobec,et al.  The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer , 2012, Histopathology.

[58]  K. Schuebel,et al.  De novo CpG island methylation in human cancer cells. , 2006, Cancer research.

[59]  A. Goel,et al.  Epigenetics of colorectal cancer. , 2012, Gastroenterology.

[60]  R. Salehi,et al.  Methylation pattern of ALX4 gene promoter as a potential biomarker for blood-based early detection of colorectal cancer , 2015, Advanced biomedical research.

[61]  P. Jean-Pierre,et al.  The effect of secondhand smoke exposure on the association between active cigarette smoking and colorectal cancer , 2010, Cancer Causes & Control.

[62]  F. Farassati,et al.  Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis , 2015, BMC Public Health.

[63]  D. Jäger,et al.  Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting , 2016, Oncotarget.

[64]  Y. Sakamoto,et al.  Epigenetic field cancerization in gastrointestinal cancers. , 2016, Cancer Letters.

[65]  Feiran Wang,et al.  Downregulation of microRNA-132 by DNA hypermethylation is associated with cell invasion in colorectal cancer , 2015, OncoTargets and therapy.

[66]  A. Rao,et al.  DNA methylation and hydroxymethylation in hematologic differentiation and transformation. , 2015, Current opinion in cell biology.

[67]  W. Garrett,et al.  Gut Microbiota, Inflammation, and Colorectal Cancer. , 2016, Annual review of microbiology.

[68]  Charles J. Kahi,et al.  Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. , 2016, Gastroenterology.

[69]  M. Verma,et al.  Epigenetics in cancer: implications for early detection and prevention. , 2002, The Lancet. Oncology.

[70]  Dawn Provenzale,et al.  Five-year colon surveillance after screening colonoscopy. , 2007, Gastroenterology.

[71]  Ulrich Keilholz,et al.  Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack , 2014, Biotechnology journal.

[72]  A. Chan,et al.  Nutrients, foods, and colorectal cancer prevention. , 2015, Gastroenterology.

[73]  K. Nephew,et al.  Hypermethylation of the TGF-β target, ABCA1 is associated with poor prognosis in ovarian cancer patients , 2015, Clinical Epigenetics.

[74]  M. Verma.  The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools. , 2015, Advances in experimental medicine and biology.

[75]  Walter C Willett,et al.  Diet and cancer: an evolving picture. , 2005, JAMA.

[76]  Kelly M. McGarvey,et al.  Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. , 2009, Cancer research.

[77]  T. Ushijima,et al.  Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway , 2015, Autophagy.

[78]  J. Jass,et al.  Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. , 2007, European journal of cancer.

[79]  E. Álvarez-Buylla,et al.  The impact of Polycomb group (PcG) and Trithorax group (TrxG) epigenetic factors in plant plasticity. , 2015, The New phytologist.

[80]  M. Gariboldi,et al.  Methylation status in patients with early stage colon cancer: A new prognostic marker? , 2012, International journal of cancer.

[81]  Jaw-Yuan Wang,et al.  Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer1 , 2016, Translational oncology.

[82]  C. Tournigand,et al.  Stage II and Stage III Colon Cancer: Treatment Advances and Future Directions , 2010, Cancer journal.

[83]  E. Scarano,et al.  DNA Methylation , 1973, Nature.

[84]  P. Scheet,et al.  Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. , 2016, Cancer research.

[85]  S. Lassmann,et al.  Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer , 2011, Epigenetics.

[86]  A. Poullis,et al.  Colorectal mucus non‐invasively collected from patients with inflammatory bowel disease and its suitability for diagnostic cytology , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[87]  O. Markowitz,et al.  Defining Field Cancerization of the Skin Using Noninvasive Optical Coherence Tomography Imaging to Detect and Monitor Actinic Keratosis in Ingenol Mebutate 0.015%- Treated Patients. , 2016, The Journal of clinical and aesthetic dermatology.

[88]  I. Zlobec,et al.  Comprehensive analysis of CpG island methylator phenotype (CIMP)‐high, ‐low, and ‐negative colorectal cancers based on protein marker expression and molecular features , 2011, The Journal of pathology.

[89]  A. Hölscher,et al.  Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome , 2009, Journal of Cancer Research and Clinical Oncology.

[90]  S. O'keefe,et al.  Diet, microbiota, and dysbiosis: a 'recipe' for colorectal cancer. , 2016, Food & function.

[91]  Wei Zhang,et al.  Examining plasma microRNA markers for colorectal cancer at different stages , 2016, Oncotarget.

[92]  H. Putter,et al.  Histone trimethylation at H 3 K 4 , H 3 K 9 and H 4 K 20 correlates with patient survival and tumor recurrence in early-stage colon cancer , 2014 .

[93]  S. Patra,et al.  Clusterin gene is predominantly regulated by histone modifications in human colon cancer and ectopic expression of the nuclear isoform induces cell death. , 2015, Biochimica et biophysica acta.

[94]  K. Ekwall,et al.  Epigenetics, chromatin and genome organization: recent advances from the ENCODE project , 2014, Journal of internal medicine.

[95]  N. Cho,et al.  Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location , 2013, British Journal of Cancer.

[96]  Somy Yoon,et al.  HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases , 2016, Chonnam medical journal.

[97]  H. Aburatani,et al.  Methylation epigenotypes and genetic features in colorectal laterally spreading tumors , 2014, International journal of cancer.

[98]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[99]  Shuji Ogino,et al.  Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review , 2011, International journal of cancer.

[100]  S. Asioli,et al.  The impact of field cancerization on the extent of duct carcinoma in situ (DCIS) in breast tissue after conservative excision. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[101]  R. Goldbohm,et al.  The Netherlands Cohort Study – Meat Investigation Cohort; a population-based cohort over-represented with vegetarians, pescetarians and low meat consumers , 2013, Nutrition Journal.

[102]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[103]  H. Flint,et al.  ‘ Diet, gut microbiology and human health , 2015 .

[104]  N. Perrin,et al.  More comprehensive discussion of CRC screening associated with higher screening. , 2013, The American journal of managed care.

[105]  F. Donnellan,et al.  Endoscopic Resection of Malignant Colonic Polyps: Why Clinicopathological Correlation (CPC) Is Needed for Optimal Treatment of CRC? , 2015, Digestive Diseases and Sciences.

[106]  Mukesh Verma,et al.  Epigenome-Wide Association Studies (EWAS) in Cancer , 2012, Current genomics.

[107]  G. Friedman,et al.  Alcohol intake, beverage choice, and cancer: a cohort study in a large kaiser permanente population. , 2015, The Permanente journal.

[108]  M. McCullough,et al.  Association between red and processed meat intake and mortality among colorectal cancer survivors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  J. Skibber,et al.  Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. , 2015, JAMA surgery.

[110]  T. Levin,et al.  Accuracy of Fecal Immunochemical Tests for Colorectal Cancer , 2014, Annals of Internal Medicine.

[111]  Yudan Chi,et al.  MicroRNAs in colorectal carcinoma - from pathogenesis to therapy , 2016, Journal of Experimental & Clinical Cancer Research.

[112]  Hong Chen,et al.  Silencing of Wnt5a during colon cancer metastasis involves histone modifications of the gene , 2011, Epigenetics.

[113]  Swati G. Patel,et al.  Practical Opportunities to Improve Early Detection and Prevention of Colorectal Cancer (CRC) in Members of High-Risk Families , 2015, Digestive Diseases and Sciences.

[114]  R. Lamerz,et al.  Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer , 2014, BMC Cancer.

[115]  H. Nemoto,et al.  FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. , 2012, Anticancer research.

[116]  Charles J. Kahi,et al.  Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. , 2016, Gastrointestinal endoscopy.

[117]  A Comprehensive Meta-Analysis of MicroRNAs for Predicting Colorectal Cancer , 2016, Medicine.

[118]  Gui-yuan Li,et al.  NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer , 2010, BMC Cancer.

[119]  H. Putter,et al.  Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer , 2014, BMC Cancer.

[120]  M. Verma,et al.  Epigenetics and Cancer , 2004, Critical reviews in clinical laboratory sciences.

[121]  U. Gezer,et al.  Histone Methylation Marks on Circulating Nucleosomes as Novel Blood-Based Biomarker in Colorectal Cancer , 2015, International journal of molecular sciences.

[122]  A. Buonadonna,et al.  HLA-G 3’UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment , 2015, PloS one.

[123]  H. Brenner,et al.  Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review , 2016, Clinical Epigenetics.

[124]  D. Lieberman.  Colon-polyp surveillance--do patients benefit? , 2014, The New England journal of medicine.

[125]  Jennifer Herrick,et al.  Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. , 2006, Journal of the National Cancer Institute.

[126]  Perry J. Pickhardt,et al.  Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection , 2016, Abdominal Radiology.

[127]  N. Ahuja,et al.  Epigenetic therapy in gastrointestinal cancer: the right combination , 2016, Therapeutic advances in gastroenterology.

[128]  Alison R. T. Brenner,et al.  Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years , 2016, The American Journal of Gastroenterology.

[129]  M. Verma,et al.  Epigenetic therapy for colorectal cancer. , 2015, Methods in molecular biology.

[130]  J. Cerhan,et al.  Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. , 2010, Journal of the National Cancer Institute.

[131]  D. Lieberman.  Colon polyp surveillance: clinical decision tool. , 2014, Gastroenterology.

[132]  L. Strong,et al.  Activating mutation in MET oncogene in familial colorectal cancer , 2011, BMC Cancer.

[133]  D. English,et al.  The Melbourne Collaborative Cohort Study. , 2002, IARC scientific publications.

[134]  J. Manson,et al.  The Nurses' Health Study: 20-year contribution to the understanding of health among women. , 1997, Journal of women's health.

[135]  J. O. Lee,et al.  Promoter hypermethylation of membrane type 3 matrix metalloproteinase is associated with cell migration in colorectal adenocarcinoma. , 2015, Cancer genetics.

[136]  Christopher F. Martin,et al.  Food groups and colon cancer risk in African‐Americans and Caucasians , 2004, International journal of cancer.

[137]  H. Aburatani,et al.  Three DNA Methylation Epigenotypes in Human Colorectal Cancer , 2009, Clinical Cancer Research.

[138]  M. Gariboldi,et al.  Circulating free DNA in a screening program for early colorectal cancer detection. , 2014, Tumori.

[139]  Beth A. Glenn,et al.  Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first‐degree relatives , 2015, Cancer.

[140]  Jie Lin,et al.  miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression , 2016, Oncotarget.

[141]  A. Gerger,et al.  Current Status of Long Non-Coding RNAs in Human Cancer with Specific Focus on Colorectal Cancer , 2014, International journal of molecular sciences.

[142]  Peter W. Laird,et al.  Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[143]  D. Lieberman,et al.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer , 2017, The American Journal of Gastroenterology.

[144]  C. Ferreira,et al.  Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. , 2016, Clinical colorectal cancer.

[145]  K. Robertson,et al.  DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. , 2009, Cancer research.

[146]  Harry J. Flint,et al.  The gut microbiota, bacterial metabolites and colorectal cancer , 2014, Nature Reviews Microbiology.

[147]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[148]  Histone H3 lysine 27 acetylation is altered in colon cancer , 2014, Clinical Proteomics.

[149]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[150]  Joobae Park,et al.  Aberrant Methylation of APC, MGMT, RASSF2A, and Wif-1 Genes in Plasma as a Biomarker for Early Detection of Colorectal Cancer , 2009, Clinical Cancer Research.

[151]  M. Morente,et al.  KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer , 2013, Tumor Biology.

[152]  R. Soong,et al.  Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer , 2014, Cancer.

[153]  S. Carter,et al.  Barriers to and facilitators of colorectal cancer screening in different population subgroups in Adelaide, South Australia , 2012, The Medical journal of Australia.

[154]  M. Copin,et al.  MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer , 2015, International journal of cancer.

[155]  R. Lothe,et al.  Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers , 2008, Molecular Cancer.

[156]  D. Weed,et al.  Red Meat and Colorectal Cancer: A Quantitative Update on the State of the Epidemiologic Science , 2015, Journal of the American College of Nutrition.

[157]  Xiang-Jiao Yang,et al.  Molecular and Functional Characterization of Histone Deacetylase 4 (HDAC4). , 2016, Methods in molecular biology.

[158]  H. Schulten,et al.  Methylation of the Polycomb Group Target Genes Is a Possible Biomarker for Favorable Prognosis in Colorectal Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[159]  P. Kuppen,et al.  DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence , 2014, Apoptosis.